ABCB1 and ovarian cancer: One of the earliest identified resistance mechanisms was the upregulation of the ABCB1 (MDR1, P-glycoprotein) drug efflux transporter, which reduces intracellular drug accumulation [48] and has been observed in both PARPi- and platinum-resistant ovarian cancer cells [49].